Napredna pretraga

Pregled bibliografske jedinice broj: 514971

Clinical applicability of tumor marker CYFRA 21-1 in patients with NSCLC: a longitudinal study of 500 patients during 2 years


Pavićević, Radomir; Bialk, Peter; Bubanović, Gordana; Krajna, Ana; Samaržija, Miroslav; Pavićević, Lukrecija
Clinical applicability of tumor marker CYFRA 21-1 in patients with NSCLC: a longitudinal study of 500 patients during 2 years // Gene Functional Analysis
San Francisco, SAD, 2001. (poster, nije recenziran, sažetak, znanstveni)


Naslov
Clinical applicability of tumor marker CYFRA 21-1 in patients with NSCLC: a longitudinal study of 500 patients during 2 years

Autori
Pavićević, Radomir ; Bialk, Peter ; Bubanović, Gordana ; Krajna, Ana ; Samaržija, Miroslav ; Pavićević, Lukrecija

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Gene Functional Analysis / - , 2001

Skup
Cambridge Healthtech Institute's fifth annual «Gene Funcional analysis: Genome 2001» tri-conference

Mjesto i datum
San Francisco, SAD, 8-9.3.2001

Vrsta sudjelovanja
Poster

Vrsta recenzije
Nije recenziran

Ključne riječi
CYFRA 21-1; NSCLC; tumor marker

Sažetak
The clinical application of cytokeratin marker CYFRA 21-1 was standardized on 2000 patients. In all patients the star value of CYFRA 21-1 was determined before therapy (Roche Diagnoastics). Tumor marker CYFRA 21-1 was ssessed longitudinally 1 to 24 months after the therapy, or before the next therapy. On eto three months after the surgical treatment in 87% of the patients the marker values decreased to the healthy population level...

Izvorni jezik
Engleski

Znanstvena područja
Biologija, Kliničke medicinske znanosti



POVEZANOST RADA